Joshua Samuel

Apr 9, 2024 | rapzilla.com | Joshua Samuel

In the realm of music, diversity has become a powerful force, shaping and reshaping genres in ways that challenge traditional boundaries. One such genre that has undergone a fascinating transformation is Christian Rap. For individuals who identify as South Asian, being a minority in this sub-genre comes with its unique set of experiences and challenges. This article explores the journey of a couple of South Asian artists you may know in the Christian Hip-Hop scene.

Feb 12, 2024 | lexology.com | Harriet Hanks |Kristen Riemenschneider |James Smith |Jake Reynolds |Elizabeth K. Bieber |Christopher Stothers | +4 more

Antimicrobial resistance (AMR) is a growing global threat: the WHO recognises it as one of the top public health and development threats, and bacterial AMR was associated with almost 5 million global deaths in a single year in one landmark study.1 AMR’s contributing factors include a lack of new antimicrobial products, limited access to antibiotics in low- and middle-income countries, and discharge of antimicrobial waste into the environment.

May 2, 2023 | edcircuit.com | Joshua Samuel

0 How do we ensure equitable resources for students to attend college and achieve post-secondary success? In this episode of Conference Connections, an interview series with K20 thought leaders, we chat with Joshua Samuel, Founder & CEO of Coins for College. The edCircuit team caught up with Joshua at FETC 2023. The topic of this discussion was college planning, resources for students, and how to equitably share resources with the students who need them for post-secondary success.

Apr 12, 2023 | lexology.com | Kristen Riemenschneider |Joshua Samuel

In our January blog post on this topic, The Drug Pricing Landscape in 2023: Renewed Pressure for Pricing Reform, we speculated that in 2023 we could see changes in the regulation of drug pricing in the U.S. It’s only the beginning of April and there have already been some notable developments—albeit in multiple directions. First, we saw some movement towards greater control over drug prices.